Major Events - Universal Medical (02666) plans to invest 15.03 million yuan to establish a joint venture that will create a collaborative platform integrating policy alignment, technology transfer, and clinical validation [1] - Fosun Pharma (02196) subsidiary has had its drug registration application for polyethylene glycol electrolyte solution accepted by the National Medical Products Administration [1] - China Biologic Products (01177) received approval from NMPA for the clinical trial application of LM-350 "CDH17 ADC" [1] - Xianruida Medical-B (06669) has received approval from the National Medical Products Administration for the registration of its coronary overall exchange balloon dilation catheter [1] - Meili Tianyuan Medical Health (02373) subsidiary plans to acquire medical and beauty assets related to Nairuier for 40 million yuan, adding 19 direct-operated stores [1] - China Tongru (01763) has exported its self-produced irradiation equipment to the Latin American market for the first time [1] Operating Performance - Trip.com Group-S (09961) reported a third-quarter net profit of 19.89 billion yuan, an increase of 194.01% year-on-year [1] - H&H International Holdings (01112) reported a 12.0% year-on-year increase in total revenue for the first three quarters [1] - Weibo-SW (09898) reported a net profit attributable to shareholders of 454 million USD for the third quarter, an increase of 55.43% year-on-year [1] - Baidu Group-SW (09888) reported total revenue of 31.2 billion yuan in the third quarter, with AI new business revenue growing over 50% year-on-year [1] - Xiaomi Group-W (01810) achieved a record adjusted net profit of 11.31 billion yuan in the third quarter, with smartphone shipments increasing year-on-year for nine consecutive quarters [1] - China Oriental Group (00581) reported sales of approximately 2.1 million tons of self-produced steel products in the third quarter [1] - BOSS Zhipin-W (02076) reported an adjusted net profit of approximately 999.2 million yuan in the third quarter, an increase of 34.2% year-on-year [1]

Core Viewpoint - The company, Xianruida Medical-B (06669), has received registration approval from the National Medical Products Administration of China for its coronary overall exchange balloon dilation catheter, Jingyi®, which is designed to improve myocardial perfusion in patients with coronary artery stenosis [1] Group 1: Product Details - Jingyi® is suitable for balloon dilation at sites of coronary artery stenosis or bypass graft stenosis, with balloon diameters ranging from 2.0 to 5.0 mm also applicable for post-stent dilation [1] - The product features a semi-compliant balloon dilation catheter with a smaller head diameter and optimized delivery system, enhancing its passability and pushability [1] - Jingyi® effectively addresses complex lesions such as chronic total occlusions and severe calcifications, improving surgical efficiency and safety through its overall exchange design [1] Group 2: Market Strategy - The company plans to conduct marketing activities in China at an appropriate time following the approval [1]

Core Viewpoint - The company, Xianruida Medical-B (06669.HK), has received approval from the National Medical Products Administration of China for its coronary overall exchange balloon dilation catheter, Jingyi®, which is designed to improve myocardial perfusion in patients with coronary artery stenosis [1] Group 1: Product Approval - The approval was granted on November 13, 2025, for the Jingyi® balloon dilation catheter [1] - The product is suitable for balloon dilation at sites of coronary artery stenosis or bypass graft stenosis [1] - The catheter features a diameter range of 2.0-5.0mm, which is also applicable for post-stent dilation [1] Group 2: Product Features - Jingyi® is a semi-compliant balloon dilation catheter that offers superior passability and pushability due to its smaller head diameter and optimized delivery system [1] - The design effectively addresses complex lesions such as chronic total occlusions and severe calcifications [1] - The overall exchange design enhances surgical efficiency and safety [1] Group 3: Marketing Plans - The company plans to initiate marketing activities in China at an appropriate time following the approval [1]